Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.
cholangiocarcinoma
myositis
precision oncology
targeted therapy
Journal
Journal of immunotherapy and precision oncology
ISSN: 2590-017X
Titre abrégé: J Immunother Precis Oncol
Pays: United States
ID NLM: 101768397
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
28
08
2021
revised:
13
11
2021
accepted:
15
11
2021
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma is a rare malignancy, which is rich in actionable alterations. Genomic aberrations in the mitogen-activated protein kinase (MAPK) pathway are common, and
Identifiants
pubmed: 35663835
doi: 10.36401/JIPO-21-18
pmc: PMC9138421
doi:
Types de publication
Case Reports
Langues
eng
Pagination
26-30Déclaration de conflit d'intérêts
Conflicts of Interest: Vivek Subbiah reports research funding/grant support for clinical trials from Roche/ Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, Univesity of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals; travel support from Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte. Consultancy/ Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED pharma, Medimmune, Novartis, Relay Therapeutics, and Roche; and other support from Medscape. Funda Meric-Bernstam reports consulting fees from F. Hoffman-La Roche Ltd., Genentech Inc., Pfizer Inc. and sponsored research to the institution from Genentech Inc. The remaining authors have no relevant disclosures.
Références
Autoimmun Rev. 2019 Mar;18(3):223-230
pubmed: 30639649
Rheumatology (Oxford). 2018 Aug 1;57(8):1497-1499
pubmed: 29617934
Ann Surg Oncol. 2014 Nov;21(12):3827-34
pubmed: 24889489
Melanoma Res. 2017 Oct;27(5):511-515
pubmed: 28692456
Hum Pathol. 2013 Dec;44(12):2768-73
pubmed: 24139215
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Am J Clin Dermatol. 2017 Dec;18(6):745-754
pubmed: 28537004
PLoS One. 2015 Nov 06;10(11):e0141903
pubmed: 26544592
JCO Precis Oncol. 2020 Jun 1;4:
pubmed: 32923885
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Oncotarget. 2016 Jul 19;7(29):46750-46767
pubmed: 27102149
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Gynecol Oncol. 2020 Feb;156(2):301-307
pubmed: 31870556
Invest New Drugs. 2015 Jun;33(3):641-51
pubmed: 25809858
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
J Gastrointest Oncol. 2016 Dec;7(6):E98-E102
pubmed: 28078132
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
Clin Cancer Res. 2012 Sep 1;18(17):4794-805
pubmed: 22767668
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
J Neurol Sci. 2015 Apr 15;351(1-2):13-17
pubmed: 25765229
Lancet Oncol. 2017 Apr;18(4):464-472
pubmed: 28268064
Exp Mol Pathol. 2015 Oct;99(2):240-4
pubmed: 26189129
Eur J Cancer. 2013 May;49(7):1521-9
pubmed: 23433846
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
J Gastrointest Oncol. 2017 Apr;8(2):E32-E38
pubmed: 28480077
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
ESMO Open. 2019 May 23;4(3):e000491
pubmed: 31231568